Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Mar-Apr;29(2):104-8.
doi: 10.1111/dth.12318. Epub 2015 Nov 11.

Use of Becaplermin for nondiabetic ulcers: pyoderma gangrenosum and calciphylaxis

Affiliations
Case Reports

Use of Becaplermin for nondiabetic ulcers: pyoderma gangrenosum and calciphylaxis

Olivia Twu et al. Dermatol Ther. 2016 Mar-Apr.

Abstract

Large difficult to heal ulcers of various etiologies carry a high morbidity and mortality rate. Becaplermin is a recombinant platelet-derived growth factor approved for treatment of diabetic ulcers. In this two-case series, we report the use of becaplermin in the treatment of ulcers due to (i) calciphylaxis, an often fatal condition resulting from systemic calcification and thrombosis of vessels and (ii) pyoderma gangrenosum (PG), a neutrophilic dermatosis. We also report that topical collagenase worsened PG ulcers, consistent with pathergy. Becaplermin can be used to help treat ulcers resulting from calciphylaxis and PG. These encouraging results lend support for the utilization of becaplermin in the treatment of nondiabetic chronic ulcers of various etiologies.

Keywords: becaplermin; calciphylaxis; pyoderma gangrenosum.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None of the authors have any conflicts of interest.

Figures

FIG. 1
FIG. 1
Histopathology of right knee. 40 × magnification, H&E stain of edge of ulcer with underlying mixed acute and chronic inflammatory infiltrate with neutrophils and eosinophils consistent with chronic pyoderma gangrenosum. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIG. 2
FIG. 2
Pyoderma gangrenosum gross photographs. A) Location of pyoderma gangrenosum lesions on right lower leg and left dorsal foot. B) Right lower leg flaring at the beginning of the patient’s last hospitalization showing a large ulcer with undermined borders and granulation tissue. C, D) Improvement in the size and extent of the ulceration over time at 3 and 7 weeks post-treatment as patient was treated with prednisone and becaplermin, with progression to pink atrophic plaques and hyperpigmented cribiform scars. E) Left dorsal foot with a large ulcer with undermined borders and crust. F, G) Resolution of left dorsal foot ulcer at 3 and 7 weeks post-treatment showing replacement with pink atrophic plaque. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIG. 3
FIG. 3
Calciphylaxis gross photographs and pathology. A) Retiform purpura visible on left anterior shin as well as large ulcer of the left medial calf. B, C) Left medial calf after 3 and 8 weeks of daily therapy with 0.01% becaplermin gel. D) Histopathology of ulcer at 40 × magnification, von Kossa stain highlights calcium deposition within medium-sized vessel walls, consistent with calciphylaxis. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Similar articles

Cited by

  • Calciphylaxis.
    Nigwekar SU. Nigwekar SU. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276-281. doi: 10.1097/MNH.0000000000000328. Curr Opin Nephrol Hypertens. 2017. PMID: 28375870 Free PMC article. Review.
  • Progressive Necrotic Black Eschar and Reticular Purpura: A Quiz.
    Lin ZT, Hong-Hao Hu, Hao Guo, Jiu-Hong Li. Lin ZT, et al. Acta Derm Venereol. 2023 May 10;103:adv4540. doi: 10.2340/actadv.v103.4540. Acta Derm Venereol. 2023. PMID: 37165684 Free PMC article. No abstract available.

References

    1. Prat L, Bouaziz J, Wallach D, Vignon-Pennamen M, Bagot M. Neutrophilic dermatoses as systemic diseases. Clin Dermatol. 2014;32:376–388. - PubMed
    1. Jacob SE, Martin LK, Kerdel FA. Cutaneous Wegener’s granulomatosis (malignant pyoderma) in a patient with Crohn’s disease. Int J Dermatol. 2003;42:896–898. - PubMed
    1. Setterfield J, Shirlaw PJ, Challacombe SJ, Black MM. Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinaemia. Br J Dermatol. 2001;144:393–396. - PubMed
    1. Batalla A, Perez-Pedrosa A, Garcia-Doval I, Gonzalez-Barcala FJ, Roson E, De la Torre C. Lung involvement in pyoderma gangrenosum: a case report and review of the literature. Actas Dermosifiliogr. 2011;102(5):373–377. - PubMed
    1. Gade M, Studstrup F, Andersen AK, Hilberg O, Fogh C, Bendstrup E. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med. 2015;109:443–450. - PubMed

Publication types

Substances

LinkOut - more resources